Brett Mahon

Prof. Brett Mahon

Rush University Medical Center
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
NBNike Beaubier
Nike Beaubier
RTRobert Tell
Robert Tell
DLDenise Lau
Denise Lau
JPJerod R. Parsons
Jerod R. Parsons
SBStephen Bush
Stephen Bush
KWKevin P. White
Kevin P. White
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

1 January 2019 in Journal of Pathology Informatics
Verified
Journal Article
Open access
PDF file
LSLingdao Sha
Lingdao Sha
BOBoleslaw L. Osinski
Boleslaw L. Osinski
IHIrvin Y. Ho
Irvin Y. Ho
TTTimothy L. Tan
Timothy L. Tan
CWCaleb Willis
Caleb Willis
SYStephen S. F Yip
Stephen S. F Yip
Background: Tumor programmed death-ligand 1 (PD-L1) status is useful in determining which patients may benefit from programmed death-1 (PD-1)/PD-L1 inhibitors. However, little is known about the association between PD-L1 status and tumor histopathological patterns. Using deep learning, we predicted PD-L1 status from hematoxylin and eosin (H and E) whole-slide images (WSIs) of nonsmall cell lung cancer (NSCLC) tumor samples. Materials and Methods: One hundred and thirty NSCLC patients were randomly assigned to training (n = 48) or test (n = 82) cohorts. A pair of H and E and PD-L1-immunostained WSIs was obtained for each patient. A pathologist annotated PD-L1 positive and negative tumor regions on the training samples using immunostained WSIs for reference. From the H and E WSIs, over 145,000 training tiles were generated and used to train a multi-field-of-view deep learning model with a residual neural network backbone. Results: The trained model accurately predicted tumor PD-L1 status on the held-out test cohort of H and E WSIs, which was balanced for PD-L1 status (area under the receiver operating characteristic curve [AUC] =0.80, P << 0.01). The model remained effective over a range of PD-L1 cutoff thresholds (AUC = 0.67–0.81, P ≤ 0.01) and when different proportions of the labels were randomly shuffled to simulate interpathologist disagreement (AUC = 0.63–0.77, P ≤ 0.03). Conclusions: A robust deep learning model was developed to predict tumor PD-L1 status from H and E WSIs in NSCLC. These results suggest that PD-L1 expression is correlated with the morphological features of the tumor microenvironment.

2 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
XCXiaoli Chen
Xiaoli Chen
HCHankui Chen
Hankui Chen
MDMeiyu Dai
Meiyu Dai
JAJunmei Ai
Junmei Ai
YLYan Li
Yan Li
YDYouping Deng
Youping Deng
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions

1 January 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
SDShaun Daly
Shaun Daly
DRDaniel Rinewalt
Daniel Rinewalt
CFCristina Fhied
Cristina Fhied
SBSanjib Basu
Sanjib Basu
BMBrett Mahon
Brett Mahon
Jeffrey A. BorgiaJeffrey A. Borgia
Jeffrey A. Borgia
The recent findings of the National Lung Screening Trial showed 24.2% of individuals at high risk for lung cancer having one or more indeterminate nodules detected by low-dose computed tomography-based screening, 96.4% of which were eventually confirmed as false positives. These positive scans necessitate additional diagnostic procedures to establish a definitive diagnosis that adds cost and risk to the paradigm. A plasma test able to assign benign versus malignant pathology in high-risk patients would be an invaluable tool to complement low-dose computed tomography-based screening and promote its rapid implementation. We evaluated 17 biomarkers, previously shown to have value in detecting lung cancer, against a discovery cohort, comprising benign (n = 67) cases and lung cancer (n = 69) cases. A Random Forest method based analysis was used to identify the optimal biomarker panel for assigning disease status, which was then validated against a cohort from the Mayo Clinic, comprising patients with benign (n = 61) or malignant (n = 20) indeterminate lung nodules. Our discovery efforts produced a seven-analyte plasma biomarker panel consisting of interleukin 6 (IL-6), IL-10, IL-1ra, sIL-2Rα, stromal cell-derived factor-1α+β, tumor necrosis factor α, and macrophage inflammatory protein 1 α. The sensitivity and specificity of our panel in our validation cohort is 95.0% and 23.3%, respectively. The validated negative predictive value of our panel was 93.8%. We developed a seven-analyte plasma biomarker panel able to identify benign nodules, otherwise deemed indeterminate, with a high degree of accuracy. This panel may have clinical utility in risk-stratifying screen-detected lung nodules, decrease unnecessary follow-up imaging or invasive procedures, and potentially avoid unnecessary morbidity, mortality, and health care costs.

1 November 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
DSDavid D. Shersher
David D. Shersher
MVMichael S. Vercillo
Michael S. Vercillo
CFCristina Fhied
Cristina Fhied
SBSanjib Basu
Sanjib Basu
OROmid Rouhi
Omid Rouhi
JBJeffrey A. Borgia
Jeffrey A. Borgia

1 August 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JMJoshua Melson
Joshua Melson
KMKaren Ma
Karen Ma
SASaba Arshad
Saba Arshad
MGMichael Greenspan
Michael Greenspan
TKThomas Kaminsky
Thomas Kaminsky
SJShriram Jakate
Shriram Jakate